ESMO 2023 | A Phase I study of FHD-286, a novel BRG1/BRM inhibitor, in metastatic uveal melanoma

Sapna Patel, MD, from The University of Texas MD Anderson Cancer Center, discusses FHD-286, a novel orally administered compound inhibiting ATPase components of the BAF complex in metastatic uveal melanoma. Administered at escalating doses in a Phase I trial (NCT04879017 ), FHD-286 showed promising safety and tolerability profiles in 52 patients, with dysgeusia and fatigue as common adverse events. Notably, a patient in the 10 mg QD dosing cohort achieved a partial response, sustaining treatment for 16 months, and prolonged stable disease was observed. No treatment-related deaths occurred. While the recommended phase II dose is undetermined, ongoing analysis suggests FHD-286 accumulates with daily dosing. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.